Glenmark Pharmaceuticals is doing good today; from its close of Rs.1080.05, the stock opened today at Rs.1092.60, its intraday high and quite close to its 52-week high of Rs.1095.95. Its come off this level and is presently trading at Rs.1082 levels.

The company announced today morning that it has received final approval from the US FDA for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC).

This is bioequivalent1 to Advil2 Dual Action with Acetaminophen Tablets, 250 mg/125 mg (OTC), of Haleon US Holdings.

These tablets will be distributed in the U.S. by Glenmark Therapeutics Inc., USA.

According to Nielsen syndicated data for the latest 52 weeks period ending March 23, 2024, the Advil Dual Action with Acetaminophen Tablets, 250 mg/125 mg (OTC) achieved annual sales of approximately $84.1 million.

Glenmark’s current portfolio consists of 195 products authorized for distribution in the U.S. marketplace and 52 ANDA’s pending approval with the U.S. FDA.